Innovations for the elimination and control of visceral leishmaniasis.
作者信息
Selvapandiyan Angamuthu, Croft Simon L, Rijal Suman, Nakhasi Hira L, Ganguly Nirmal K
机构信息
Institute of Molecular Medicine, Jamia Hamdard, New Delhi, India.
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
出版信息
PLoS Negl Trop Dis. 2019 Sep 19;13(9):e0007616. doi: 10.1371/journal.pntd.0007616. eCollection 2019 Sep.
Abstract
摘要
相似文献
1
Innovations for the elimination and control of visceral leishmaniasis.用于消除和控制内脏利什曼病的创新措施。
PLoS Negl Trop Dis. 2019 Sep 19;13(9):e0007616. doi: 10.1371/journal.pntd.0007616. eCollection 2019 Sep.
2
Visceral Leishmaniasis Caused by Leishmania donovani Zymodeme MON-37, Western Ghats, India.印度西高止山脉由杜氏利什曼原虫酶谱型MON - 37引起的内脏利什曼病。
Emerg Infect Dis. 2020 Aug;26(8):1956-1958. doi: 10.3201/eid2608.200557.
3
Prevention of Leishmania donovani infection.杜氏利什曼原虫感染的预防
BMJ. 2010 Dec 29;341:c6751. doi: 10.1136/bmj.c6751.
4
Incrimination of Phlebotomus (Larroussius) orientalis as a vector of visceral leishmaniasis in western Upper Nile Province, southern Sudan.认定东方白蛉（Larroussius亚属）为苏丹南部上尼罗省西部内脏利什曼病的传播媒介。
Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):622-3. doi: 10.1016/0035-9203(92)90154-5.
5
Vector control interventions for visceral leishmaniasis elimination initiative in South Asia, 2005-2010.南亚消除内脏利什曼病的病媒控制干预措施，2005-2010 年。
Indian J Med Res. 2012 Jul;136(1):22-31.
6
Revival of a focus of visceral leishmaniasis in central Sudan.苏丹中部内脏利什曼病病灶的再度出现。
Ann Trop Med Parasitol. 2008 Jan;102(1):79-80. doi: 10.1179/136485908X252269.
7
Control of the leishmaniases. Report of a WHO Expert Committee.利什曼病的防治。世界卫生组织专家委员会报告。
World Health Organ Tech Rep Ser. 1990;793:1-158.
8
Is elimination of kala-azar feasible by 2017?到2017年消除黑热病是否可行？
Indian J Med Res. 2016 Dec;144(6):799-802. doi: 10.4103/ijmr.IJMR_335_16.
9
An overview of visceral leishmaniasis elimination program in India: a picture imperfect.印度内脏利什曼病消除计划概述：一幅并不完美的图景。
Expert Rev Anti Infect Ther. 2014 Aug;12(8):929-35. doi: 10.1586/14787210.2014.928590. Epub 2014 Jun 14.
10
[Meeting "Visceral leishmaniasis in Maghreb", 2-4 April 2015 in Tunis. Recommendations].[2015年4月2日至4日于突尼斯召开的“马格里布内脏利什曼病”会议。建议]
Bull Soc Pathol Exot. 2015 Aug;108(3):229-30. doi: 10.1007/s13149-015-0435-4.
引用本文的文献
1
Mechanistic insights into LdCen1-LdDRP interaction facilitating UV-induced DNA damage repair in Leishmania donovani.杜氏利什曼原虫中促进紫外线诱导的DNA损伤修复的LdCen1与LdDRP相互作用的机制研究
Med Microbiol Immunol. 2025 Apr 9;214(1):18. doi: 10.1007/s00430-025-00825-3.
2
Design, synthesis and biological activity of peptidyl β-nitrostyrenes as cysteine protease inhibitors against .作为针对……的半胱氨酸蛋白酶抑制剂的肽基β-硝基苯乙烯的设计、合成及生物活性
RSC Adv. 2025 Feb 19;15(8):5703-5719. doi: 10.1039/d4ra06510g.
3
Robust leishmanicidal upshot of some new diphenyl triazine-based molecules.一些新型二苯基三嗪类分子具有强大的杀利什曼原虫效果。
RSC Adv. 2024 Jul 17;14(31):22587-22597. doi: 10.1039/d4ra01904k. eCollection 2024 Jul 12.
4
Manufacturing and preclinical toxicity of GLP grade gene deleted attenuated Leishmania donovani parasite vaccine.GLP 级基因缺失减毒利什曼原虫疫苗的生产和临床前毒性。
Sci Rep. 2024 Jun 25;14(1):14636. doi: 10.1038/s41598-024-64592-6.
5
Biophysical Evidence for the Amyloid Formation of a Recombinant Rab2 Isoform of .生物物理证据表明一种重组 Rab2 同工型发生淀粉样变。
Protein Pept Lett. 2024;31(4):312-322. doi: 10.2174/0109298665299157240327084614.
6
Portable smartphone-based molecular test for rapid detection of Leishmania spp.基于智能手机的便携式分子检测方法，用于快速检测利什曼原虫属。
Infection. 2024 Aug;52(4):1315-1324. doi: 10.1007/s15010-024-02179-z. Epub 2024 Feb 14.
7
Evaluation of a Point-of-Need Molecular Diagnostic Tool Coupled with Rapid DNA Extraction Methods for Visceral Leishmaniasis.一种用于内脏利什曼病的即时需求分子诊断工具与快速DNA提取方法的评估
Diagnostics (Basel). 2023 Dec 11;13(24):3639. doi: 10.3390/diagnostics13243639.
8
Antimony resistance and gene expression in : spotlight on molecular and proteomic aspects.抗锑性与 : 分子和蛋白质组学方面的基因表达研究焦点。
Parasitology. 2024 Jan;151(1):1-14. doi: 10.1017/S0031182023001129. Epub 2023 Nov 28.
9
Visceral Leishmaniasis Associated with HIV Coinfection in Pará, Brazil.巴西帕拉州内脏利什曼病与HIV合并感染
HIV AIDS (Auckl). 2023 May 25;15:247-255. doi: 10.2147/HIV.S400189. eCollection 2023.
10
Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis-An updated review.当前化疗的局限性以及基于纳米制剂的两性霉素B用于内脏利什曼病治疗的未来——最新综述
Front Bioeng Biotechnol. 2022 Dec 14;10:1016925. doi: 10.3389/fbioe.2022.1016925. eCollection 2022.
本文引用的文献
1
Development of a Multiplexed Assay for Detection of and Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis.开发一种多重分析检测试剂盒，用于检测内脏利什曼病患者尿液样本中的 和 蛋白生物标志物。
J Clin Microbiol. 2019 Apr 26;57(5). doi: 10.1128/JCM.02076-18. Print 2019 May.
2
Eliminating visceral leishmaniasis in South Asia: the road ahead.消除南亚内脏利什曼病：前路漫漫。
BMJ. 2019 Jan 22;364:k5224. doi: 10.1136/bmj.k5224.
3
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.一项随机试验，比较两性霉素 B 脂质体单药治疗与两性霉素 B 脂质体联合米替福新治疗合并 HIV 感染的内脏利什曼病患者的疗效，该试验在埃塞俄比亚开展。
PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006988. doi: 10.1371/journal.pntd.0006988. eCollection 2019 Jan.
4
Age trends in asymptomatic and symptomatic Leishmania donovani infection in the Indian subcontinent: A review and analysis of data from diagnostic and epidemiological studies.印度次大陆无症状和有症状利什曼原虫感染的年龄趋势：来自诊断和流行病学研究的数据的综述和分析。
PLoS Negl Trop Dis. 2018 Dec 6;12(12):e0006803. doi: 10.1371/journal.pntd.0006803. eCollection 2018 Dec.
5
Validation of SYBR green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL).基于 SYBR Green I 的封闭式管环介导等温扩增 (LAMP) 检测法和简化的直接血裂解 (DBL)-LAMP 检测法对内脏利什曼病 (VL) 的诊断的验证。
PLoS Negl Trop Dis. 2018 Nov 15;12(11):e0006922. doi: 10.1371/journal.pntd.0006922. eCollection 2018 Nov.
6
Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.定量评估卡拉巴肿后皮肤利什曼病对沙蝇的感染性。
Clin Infect Dis. 2019 Jul 2;69(2):251-258. doi: 10.1093/cid/ciy891.
7
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.内脏利什曼病治疗的最新进展：成功、陷阱和展望。
Clin Microbiol Rev. 2018 Aug 29;31(4). doi: 10.1128/CMR.00048-18. Print 2018 Oct.
8
New insights into leishmaniasis in the immunosuppressed.免疫抑制患者中利什曼病的新见解。
PLoS Negl Trop Dis. 2018 May 10;12(5):e0006375. doi: 10.1371/journal.pntd.0006375. eCollection 2018 May.
9
A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.一种可预防媒介传播内脏利什曼病的特定亚单位疫苗。
NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017.
10
Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.印度次大陆的黑热病后皮肤利什曼病：对东南亚区域消除黑热病规划的一个威胁
PLoS Negl Trop Dis. 2017 Nov 16;11(11):e0005877. doi: 10.1371/journal.pntd.0005877. eCollection 2017 Nov.
Zotero 插件